Phase 4
Completed N=40
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
Bariatric Surgery Candidate · Glucose Intolerance · Insulin Resistance
Source: ClinicalTrials.gov NCT03809182 ↗
Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcomePrimary: Plasmatic Glucose Levels (mg/dl). — 80; 82; 114; 111 mg/dl — p=0.38
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study investigated the effect of dexmedetomidine in obese patients undergoing bariatric surgery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Plasmatic Glucose Levels (mg/dl). |
80; 82; 114; 111; 124; 129 | 0.38 |
| PRIMARY Plasmatic Insulin Levels (uU/ml). |
10.5; 11.2; 11.8; 19.9; 16.7; 30.3 | 0.02 sig |
| SECONDARY Fentanyl Consumption. |
6.0; 7 | — |
| SECONDARY Amount (mg) of Morphine Consumed. |
26; 18.4 | — |
| SECONDARY Pain Scores in the First 24 Postoperative Hours. |
0; 0; 0; 0; 4; 3 | — |
| SECONDARY Sedation-agitation Scores in the First 12 Postoperative Hours. |
3; 4; 4; 4; 4; 4 | — |
| SECONDARY Postoperative Nausea and Vomiting. |
16; 19 | — |
Eligibility Criteria
Inclusion Criteria
- Obese patient (BMI>30)
- American Society of Anesthesiologists grades II or III
- Diagnosis of impaired glucose tolerance
- Undergoing sleeve gastrectomy
Exclusion Criteria
- Baseline glucose > 200mg/dl
- Diagnosis of Diabetes
- Under corticosteroids treatment
- Oral hypoglycemic medication within 7 days previous surgery
- Use of insulin within 24h previous surgery
- Allergy to any drug used in the study
Data sourced from ClinicalTrials.gov (NCT03809182). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.